Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Ancient Rome: A genetic crossroads of Europe and the Mediterranean.

Antonio ML, Gao Z, Moots HM, Lucci M, Candilio F, Sawyer S, Oberreiter V, Calderon D, Devitofranceschi K, Aikens RC, Aneli S, Bartoli F, Bedini A, Cheronet O, Cotter DJ, Fernandes DM, Gasperetti G, Grifoni R, Guidi A, La Pastina F, Loreti E, Manacorda D, Matullo G, Morretta S, Nava A, Fiocchi Nicolai V, Nomi F, Pavolini C, Pentiricci M, Pergola P, Piranomonte M, Schmidt R, Spinola G, Sperduti A, Rubini M, Bondioli L, Coppa A, Pinhasi R, Pritchard JK.

Science. 2019 Nov 8;366(6466):708-714. doi: 10.1126/science.aay6826.

PMID:
31699931
2.

Clinical outcomes associated with the use of the NexSite hemodialysis catheter with new exit barrier technology: Results from a prospective, observational multi-center registry study.

Hoggard JG, Blair RD, Montero M, Moustafa MA, Newman J, Pergola PE, Saucier N, Wheeler CJ 3rd, Mermel LA, Ross JR, Beserab AD.

PLoS One. 2019 Oct 7;14(10):e0223285. doi: 10.1371/journal.pone.0223285. eCollection 2019.

3.

Effects of Selonsertib in Patients with Diabetic Kidney Disease.

Chertow GM, Pergola PE, Chen F, Kirby BJ, Sundy JS, Patel UD; GS-US-223-1015 Investigators.

J Am Soc Nephrol. 2019 Oct;30(10):1980-1990. doi: 10.1681/ASN.2018121231. Epub 2019 Sep 10.

PMID:
31506292
4.

Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease.

Pergola PE, Fishbane S, Ganz T.

Adv Chronic Kidney Dis. 2019 Jul;26(4):272-291. doi: 10.1053/j.ackd.2019.05.002. Review.

PMID:
31477258
5.

Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.

Rossing P, Block GA, Chin MP, Goldsberry A, Heerspink HJL, McCullough PA, Meyer CJ, Packham D, Pergola PE, Spinowitz B, Sprague SM, Warnock DG, Chertow GM.

Kidney Int. 2019 Oct;96(4):1030-1036. doi: 10.1016/j.kint.2019.04.027. Epub 2019 May 16.

PMID:
31377056
6.

Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.

Rizk DV, Silva AL, Pergola PE, Toto R, Warnock DG, Chin MP, Goldsberry A, O'Grady M, Meyer CJ, McCullough PA.

Cardiorenal Med. 2019;9(5):316-325. doi: 10.1159/000500612. Epub 2019 Jun 6.

7.

Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.

Spinowitz BS, Fishbane S, Pergola PE, Roger SD, Lerma EV, Butler J, von Haehling S, Adler SH, Zhao J, Singh B, Lavin PT, McCullough PA, Kosiborod M, Packham DK; ZS-005 Study Investigators.

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):798-809. doi: 10.2215/CJN.12651018. Epub 2019 May 20.

PMID:
31110051
8.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators.

Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Erratum in: Lancet. 2019 May 11;393(10184):1936.

PMID:
30995972
9.

Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review.

Pergola PE, Pecoits-Filho R, Winkelmayer WC, Spinowitz B, Rochette S, Thompson-Leduc P, Lefebvre P, Shafai G, Bozas A, Sanon M, Krasa HB.

Pharmacoecon Open. 2019 Apr 9. doi: 10.1007/s41669-019-0132-5. [Epub ahead of print] Review.

10.

Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review.

Spinowitz B, Pecoits-Filho R, Winkelmayer WC, Pergola PE, Rochette S, Thompson-Leduc P, Lefebvre P, Shafai G, Bozas A, Sanon M, Krasa HB.

J Med Econ. 2019 Jun;22(6):593-604. doi: 10.1080/13696998.2019.1588738. Epub 2019 Mar 27.

PMID:
30813807
11.

Cerebral White Matter Hyperintensities, Kidney Function Decline, and Recurrent Stroke After Intensive Blood Pressure Lowering: Results From the Secondary Prevention of Small Subcortical Strokes ( SPS 3) Trial.

Ikeme JC, Pergola PE, Scherzer R, Shlipak MG, Catanese L, McClure LA, Benavente OR, Peralta CA.

J Am Heart Assoc. 2019 Feb 5;8(3):e010091. doi: 10.1161/JAHA.118.010091.

12.

Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy.

Gale JD, Gilbert S, Blumenthal S, Elliott T, Pergola PE, Goteti K, Scheele W, Perros-Huguet C.

Kidney Int Rep. 2018 Aug 3;3(6):1316-1327. doi: 10.1016/j.ekir.2018.07.010. eCollection 2018 Nov.

13.

Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism.

Bushinsky DA, Spiegel DM, Yuan J, Warren S, Fogli J, Pergola PE.

Clin J Am Soc Nephrol. 2019 Jan 7;14(1):103-110. doi: 10.2215/CJN.04500418. Epub 2018 Oct 31.

PMID:
30381412
14.

Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.

Block GA, Pergola PE, Fishbane S, Martins JG, LeWinter RD, Uhlig K, Neylan JF, Chertow GM.

Nephrol Dial Transplant. 2019 Jul 1;34(7):1115-1124. doi: 10.1093/ndt/gfy318.

15.

Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.

Chertow GM, Appel GB, Block GA, Chin MP, Coyne DW, Goldsberry A, Kalantar-Zadeh K, Meyer CJ, Molitch ME, Pergola PE, Raskin P, Silva AL, Spinowitz B, Sprague SM, Rossing P.

J Diabetes Complications. 2018 Dec;32(12):1113-1117. doi: 10.1016/j.jdiacomp.2018.09.005. Epub 2018 Sep 13.

16.

Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.

Kloner RA, Gross C, Yuan J, Conrad A, Pergola PE.

J Cardiovasc Pharmacol Ther. 2018 Nov;23(6):524-531. doi: 10.1177/1074248418788334. Epub 2018 Aug 14.

17.

Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure.

McCullough PA, Uhlig K, Neylan JF, Pergola PE, Fishbane S.

Am J Cardiol. 2018 Aug 15;122(4):683-688. doi: 10.1016/j.amjcard.2018.04.062. Epub 2018 May 19.

18.

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents.

Haase VH, Chertow GM, Block GA, Pergola PE, deGoma EM, Khawaja Z, Sharma A, Maroni BJ, McCullough PA.

Nephrol Dial Transplant. 2019 Jan 1;34(1):90-99. doi: 10.1093/ndt/gfy055.

19.

Hemoglobin response to ferric citrate in patients with nondialysis-dependent chronic kidney disease and iron deficiency anemia.

Pergola PE, Fishbane S, LeWinter RD, Neylan JF, Uhlig K, Block GA, Chertow GM.

Am J Hematol. 2018 Jun;93(6):E154-E156. doi: 10.1002/ajh.25088. Epub 2018 Mar 30. No abstract available.

20.

Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.

Chin MP, Bakris GL, Block GA, Chertow GM, Goldsberry A, Inker LA, Heerspink HJL, O'Grady M, Pergola PE, Wanner C, Warnock DG, Meyer CJ.

Am J Nephrol. 2018;47(1):40-47. doi: 10.1159/000486398. Epub 2018 Jan 18.

21.

Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease.

Chertow GM, Block GA, Neylan JF, Pergola PE, Uhlig K, Fishbane S.

PLoS One. 2017 Nov 29;12(11):e0188712. doi: 10.1371/journal.pone.0188712. eCollection 2017.

22.

Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET).

Komers R, Gipson DS, Nelson P, Adler S, Srivastava T, Derebail VK, Meyers KE, Pergola P, MacNally ME, Hunt JL, Shih A, Trachtman H.

Kidney Int Rep. 2017 Mar 4;2(4):654-664. doi: 10.1016/j.ekir.2017.02.019. eCollection 2017 Jul.

23.

A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.

Weir MR, Pergola PE, Agarwal R, Fink JC, Kopyt NP, Singh AK, Kumar J, Schmitt S, Schaffar G, Rudy A, McKay JP, Kanceva R.

Am J Nephrol. 2017;46(5):364-370. doi: 10.1159/000481736. Epub 2017 Oct 30.

PMID:
29084409
24.

Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study.

Pergola PE, Spiegel DM, Warren S, Yuan J, Weir MR.

Am J Nephrol. 2017;46(4):323-332. doi: 10.1159/000481270. Epub 2017 Oct 11.

25.

Patterns of blood pressure response during intensive BP lowering and clinical events: results from the secondary prevention of small subcortical strokes trial.

Ku E, Scherzer R, Odden MC, Shlipak M, White CL, Field TS, Benavente O, Pergola PE, Peralta CA.

Blood Press. 2018 Apr;27(2):73-81. doi: 10.1080/08037051.2017.1382310. Epub 2017 Sep 27.

26.

Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.

Webb DJ, Coll B, Heerspink HJL, Andress D, Pritchett Y, Brennan JJ, Houser M, Correa-Rotter R, Kohan D, Makino H, Perkovic V, Remuzzi G, Tobe SW, Toto R, Busch R, Pergola P, Parving HH, de Zeeuw D.

Drugs R D. 2017 Sep;17(3):441-448. doi: 10.1007/s40268-017-0201-0.

27.

Ferric citrate controls serum phosphorus in dialysis patients: retrospective data
.

Hain DJ, Marinaro M, Koeper DW, Rosenthal MA, Chillemi S, Huffman JM, Gerbeling T, Pritsiolas JM, Loram LC, Pergola PE.

Clin Nephrol. 2017 Jul;88(1):12-18. doi: 10.5414/CN109057.

28.

Post Hoc Analyses of Randomized Clinical Trial for the Effect of Clopidogrel Added to Aspirin on Kidney Function.

Ikeme JC, Pergola PE, Scherzer R, Shlipak MG, Benavente OR, Peralta CA.

Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1040-1047. doi: 10.2215/CJN.00100117. Epub 2017 Apr 26.

29.

Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia.

Fishbane S, Block GA, Loram L, Neylan J, Pergola PE, Uhlig K, Chertow GM.

J Am Soc Nephrol. 2017 Jun;28(6):1851-1858. doi: 10.1681/ASN.2016101053. Epub 2017 Jan 12.

30.

TARGT Gene Therapy Platform for Correction of Anemia in End-Stage Renal Disease.

Blum S, Shapir N, Miari R, Lerner B, Koren B, Doenyas-Barak K, Efrati S, Pergola PE, Schwartz D, Chernin G, Yagil Y, Guzy S, Nyska A, Neil GA.

N Engl J Med. 2017 Jan 12;376(2):189-191. doi: 10.1056/NEJMc1606202. No abstract available.

PMID:
28076704
31.

Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.

Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH.

Kidney Int. 2016 Nov;90(5):1115-1122. doi: 10.1016/j.kint.2016.07.019. Epub 2016 Sep 17.

32.

Response by Peralta et al to Letter Regarding Article, "Effect of Intensive Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke: A Post Hoc Analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial".

Peralta CA, McClure LA, Scherzer R, Odden MC, White CL, Shlipak M, Benavente O, Pergola PE.

Circulation. 2016 Jul 26;134(4):e26-7. doi: 10.1161/CIRCULATIONAHA.116.022942. No abstract available.

33.

Effect of Intensive Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke: A Post Hoc Analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial.

Peralta CA, McClure LA, Scherzer R, Odden MC, White CL, Shlipak M, Benavente O, Pergola P.

Circulation. 2016 Feb 9;133(6):584-91. doi: 10.1161/CIRCULATIONAHA.115.019657. Epub 2016 Jan 13.

34.

Achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial.

Odden MC, McClure LA, Sawaya BP, White CL, Peralta CA, Field TS, Hart RG, Benavente OR, Pergola PE.

Hypertension. 2016 Jan;67(1):63-9. doi: 10.1161/HYPERTENSIONAHA.115.06480. Epub 2015 Nov 9.

35.

Can blood pressure be lowered safely in older adults with lacunar stroke? The Secondary Prevention of Small Subcortical Strokes study experience.

White CL, Szychowski JM, Pergola PE, Field TS, Talbert R, Lau H, Peri K, Benavente OR; Secondary Prevention of Small Subcortical Strokes Study Investigators.

J Am Geriatr Soc. 2015 Apr;63(4):722-9. doi: 10.1111/jgs.13349. Epub 2015 Apr 6.

36.

A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.

Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, Wolf M, Chertow GM.

Am J Kidney Dis. 2015 May;65(5):728-36. doi: 10.1053/j.ajkd.2014.10.014. Epub 2014 Nov 4.

37.

Should Blood Pressure Targets After Lacunar Stroke Vary by Body Size? The SPS3 Trial.

Field TS, McClure LA, White CL, Pergola PE, Hart RG, Benavente OR, Hill MD; SPS3 Investigators.

Am J Hypertens. 2015 Jun;28(6):756-64. doi: 10.1093/ajh/hpu228. Epub 2014 Dec 1.

38.

Sodium zirconium cyclosilicate in hyperkalemia.

Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi W, Pergola P, Singh B.

N Engl J Med. 2015 Jan 15;372(3):222-31. doi: 10.1056/NEJMoa1411487. Epub 2014 Nov 21.

39.

Lacunar strokes in patients with diabetes mellitus: risk factors, infarct location, and prognosis: the secondary prevention of small subcortical strokes study.

Palacio S, McClure LA, Benavente OR, Bazan C 3rd, Pergola P, Hart RG.

Stroke. 2014 Sep;45(9):2689-94. doi: 10.1161/STROKEAHA.114.005018. Epub 2014 Jul 17.

40.

Achieved blood pressures in the secondary prevention of small subcortical strokes (SPS3) study: challenges and lessons learned.

Pergola PE, White CL, Szychowski JM, Talbert R, Brutto OD, Castellanos M, Graves JW, Matamala G, Pretell EJ, Yee J, Rebello R, Zhang Y, Benavente OR; SPS3 Investigators.

Am J Hypertens. 2014 Aug;27(8):1052-60. doi: 10.1093/ajh/hpu027. Epub 2014 Mar 7.

41.

Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease.

Block GA, Persky MS, Shamblin BM, Baltazar MF, Singh B, Sharma A, Pergola P, Smits G, Comelli MC.

Nephron Clin Pract. 2013;123(1-2):93-101. doi: 10.1159/000351850. Epub 2013 Jun 22.

PMID:
23797006
42.

Blood pressure after recent stroke: baseline findings from the secondary prevention of small subcortical strokes trial.

White CL, Pergola PE, Szychowski JM, Talbert R, Cervantes-Arriaga A, Clark HD, Del Brutto OH, Godoy IE, Hill MD, Pelegrí A, Sussman CR, Taylor AA, Valdivia J, Anderson DC, Conwit R, Benavente OR; SPS3 Investigators.

Am J Hypertens. 2013 Sep;26(9):1114-22. doi: 10.1093/ajh/hpt076. Epub 2013 Jun 4.

43.

Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.

Janssen RS, Mangoo-Karim R, Pergola PE, Girndt M, Namini H, Rahman S, Bennett SR, Heyward WL, Martin JT.

Vaccine. 2013 Nov 4;31(46):5306-13. doi: 10.1016/j.vaccine.2013.05.067. Epub 2013 May 30.

PMID:
23727422
44.

Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial.

SPS3 Study Group, Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, Pergola PE, Szychowski JM.

Lancet. 2013 Aug 10;382(9891):507-15. doi: 10.1016/S0140-6736(13)60852-1. Epub 2013 May 29. Erratum in: Lancet. 2013 Aug 10;382(9891):506. Coffey, C S [aded].

45.

Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

de Zeeuw D, Akizawa T, Agarwal R, Audhya P, Bakris GL, Chin M, Krauth M, Lambers Heerspink HJ, Meyer CJ, McMurray JJ, Parving HH, Pergola PE, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Warnock DG, Wittes J, Chertow GM.

Am J Nephrol. 2013;37(3):212-22. doi: 10.1159/000346948. Epub 2013 Feb 28.

46.

Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis.

Macdougall IC, Provenzano R, Sharma A, Spinowitz BS, Schmidt RJ, Pergola PE, Zabaneh RI, Tong-Starksen S, Mayo MR, Tang H, Polu KR, Duliege AM, Fishbane S; PEARL Study Groups.

N Engl J Med. 2013 Jan 24;368(4):320-32. doi: 10.1056/NEJMoa1203166.

47.

Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease.

Ruiz S, Pergola PE, Zager RA, Vaziri ND.

Kidney Int. 2013 Jun;83(6):1029-41. doi: 10.1038/ki.2012.439. Epub 2013 Jan 16. Review.

48.

An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients.

Besarab A, Zeig SN, Martin ER, Pergola PE, Whittier FC, Zabaneh RI, Schiller B, Mayo M, Francisco CA, Polu KR, Duliege AM.

BMC Nephrol. 2012 Aug 30;13:95. doi: 10.1186/1471-2369-13-95.

49.

Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial.

White CL, Szychowski JM, Roldan A, Benavente MF, Pretell EJ, Del Brutto OH, Kase CS, Arauz A, Meyer BC, Meissner I, Demaerschalk BM, McClure LA, Coffey CS, Pearce LA, Conwit R, Irby LH, Peri K, Pergola PE, Hart RG, Benavente OR; SPS3 Investigators.

J Stroke Cerebrovasc Dis. 2013 Aug;22(6):764-74. doi: 10.1016/j.jstrokecerebrovasdis.2012.03.002. Epub 2012 Apr 17.

50.

Predictors of lowering SBP to assigned targets at 12 months in the Secondary Prevention of Small Subcortical Strokes study.

Graves JW, White CL, Szychowski JM, Pergola PE, Benavente OR, Coffey CS, Hornung LN, Hart RG; SPS3 Study Investigators.

J Hypertens. 2012 Jun;30(6):1233-40. doi: 10.1097/HJH.0b013e328353968d.

Supplemental Content

Loading ...
Support Center